Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum to: 'Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target' [J Hepatol 2021 (74) 1155-1166].
Ningarhari M, Caruso S, Hirsch TZ, Bayard Q, Franconi A, Védie AL, Noblet B, Blanc JF, Amaddeo G, Ganne N, Ziol M, Paradis V, Guettier C, Calderaro J, Morcrette G, Kim Y, MacLeod AR, Nault JC, Rebouissou S, Zucman-Rossi J. Ningarhari M, et al. Among authors: noblet b. J Hepatol. 2022 May;76(5):1242-1243. doi: 10.1016/j.jhep.2022.01.019. Epub 2022 Feb 24. J Hepatol. 2022. PMID: 35221117 No abstract available.
Dual regulation of TxNIP by ChREBP and FoxO1 in liver.
Noblet B, Benhamed F, O-Sullivan I, Zhang W, Filhoulaud G, Montagner A, Polizzi A, Marmier S, Burnol AF, Guilmeau S, Issad T, Guillou H, Bernard C, Unterman T, Postic C. Noblet B, et al. iScience. 2021 Feb 20;24(3):102218. doi: 10.1016/j.isci.2021.102218. eCollection 2021 Mar 19. iScience. 2021. PMID: 33748706 Free PMC article.
Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.
Ningarhari M, Caruso S, Hirsch TZ, Bayard Q, Franconi A, Védie AL, Noblet B, Blanc JF, Amaddeo G, Ganne N, Ziol M, Paradis V, Guettier C, Calderaro J, Morcrette G, Kim Y, MacLeod AR, Nault JC, Rebouissou S, Zucman-Rossi J. Ningarhari M, et al. Among authors: noblet b. J Hepatol. 2021 May;74(5):1155-1166. doi: 10.1016/j.jhep.2020.11.052. Epub 2020 Dec 15. J Hepatol. 2021. PMID: 33338512 Free article.
Corrigendum to: "BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA" [J Hepatol (2020) 1-13].
Hirsch TZ, Negulescu A, Gupta B, Caruso S, Noblet B, Couchy G, Bayard Q, Meunier L, Morcrette G, Scoazec JY, Blanc JF, Amaddeo G, Nault JC, Bioulac-Sage P, Ziol M, Beaufrère A, Paradis V, Calderaro J, Imbeaud S, Zucman-Rossi J. Hirsch TZ, et al. Among authors: noblet b. J Hepatol. 2020 Jul;73(1):225-226. doi: 10.1016/j.jhep.2020.04.004. Epub 2020 Apr 29. J Hepatol. 2020. PMID: 32360197 No abstract available.
BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
Hirsch TZ, Negulescu A, Gupta B, Caruso S, Noblet B, Couchy G, Bayard Q, Meunier L, Morcrette G, Scoazec JY, Blanc JF, Amaddeo G, Nault JC, Bioulac-Sage P, Ziol M, Beaufrère A, Paradis V, Calderaro J, Imbeaud S, Zucman-Rossi J. Hirsch TZ, et al. Among authors: noblet b. J Hepatol. 2020 May;72(5):924-936. doi: 10.1016/j.jhep.2019.12.006. Epub 2019 Dec 18. J Hepatol. 2020. PMID: 31862487 Free article.
Volasertib preclinical activity in high-risk hepatoblastoma.
Kats D, Ricker CA, Berlow NE, Noblet B, Nicolle D, Mevel K, Branchereau S, Judde JG, Stiverson CD, Stiverson CL, Svalina MN, Settelmeyer T, Matlock K, Lathara M, Mussini C, Geller JI, Noakes C, Sloma I, Bharathy N, Cairo S, Keller C. Kats D, et al. Among authors: noblet b. Oncotarget. 2019 Nov 5;10(60):6403-6417. doi: 10.18632/oncotarget.27237. eCollection 2019 Nov 5. Oncotarget. 2019. PMID: 31741706 Free PMC article.
11 results